N-Methyl-N-Nitrosurea

N-Methyl-N-Nitrosurea

SCHEMBL3748138

CN(N=O)C(N)=O.NN=O

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
F2 P00734 2/20 0.33
PRSS1 P07477 2/20 0.33
PRSS2 P07478 2/20 0.33
PRSS3 P35030 2/20 0.33
TP53 P04637 1/20 0.31
LMNA P02545 1/20 0.30
ALOX15 P16050 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Methyl-N-Nitrosurea SCHEMBL38377 0.94
N-Methyl-N-Nitrosurea SCHEMBL28025247 0.94 ALDH1A1 (0.39) ALDH1A1F2PRSS1PRSS2PRSS3
N-Methyl-N-Nitrosurea SCHEMBL27452637 0.92
N-Methyl-N-Nitrosurea SCHEMBL27400389 0.92
N-Methyl-N-Nitrosurea SCHEMBL28057965 0.92 ALDH1A1 (0.37) ALDH1A1TP53LMNAALOX15BLM
N-Methyl-N-Nitrosurea SCHEMBL28089372 0.92
N-Methyl-N-Nitrosurea SCHEMBL27465067 0.92
N-Methyl-N-Nitrosurea SCHEMBL27534649 0.92
N-Methyl-N-Nitrosurea SCHEMBL27654363 0.87 F2 (0.35) ALDH1A1F2PRSS1PRSS2PRSS3
N-Methyl-N-Nitrosurea SCHEMBL18660152 0.86 FFAR3 (0.37) ALDH1A1TP53LMNAALOX15BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001503-B1 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2017-06-07 EP disclosed
EP-1817050-B1 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2015-04-15 EP disclosed
CN-101102789-B Diagnosis and treatment of Alzheimer's disease RHODE ISLAND HOSPITAL 2012-05-30 CN disclosed
US-7833513-B2 Treatment of Alzheimer's Disease RHODE ISLAND HOSPITAL (US) 2010-11-16 US disclosed
EP-1817050-A4 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2009-08-26 EP disclosed
EP-2001503-A2 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2008-12-17 EP disclosed
CN-101102789-A Diagnosis and treatment of Alzheimer's disease RHODE ISLAND HOSPITAL (US) 2008-01-09 CN disclosed
WO-2007123723-A2 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2007-11-01 WO disclosed
EP-1817050-A2 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2007-08-15 EP disclosed
US-20070042437-A1 Diagnosis and treatment of Alzheimer's Disease RHODE ISLAND HOSPITAL (US) 2007-02-22 US disclosed
WO-2006060753-A2 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE RHODE ISLAND HOSPITAL (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042437-A1 Diagnosis and treatment of Alzheimer's Disease IGF1R, IAPP, APP ALDH1A1 2685/4885F2 3977/4885PRSS1 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.